Skip to main content

Research Repository

Advanced Search

All Outputs (9)

Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018 (2022)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T. R., …Crooks, C. J. (2022). Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018. HemaSphere, 6(11), Article e797. https://doi.org/10.1097/HS9.0000000000000797

Hemophagocytic lymphohistiocytosis (HLH) is rare, results in high mortality, and is increasingly being diagnosed. We aimed to quantify the incidence of diagnosed HLH and examine temporal trends in relation to age and associated diseases. Using nation... Read More about Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–2018.

Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors (2022)
Presentation / Conference Contribution
Bishton, M., Crooks, C., Liu, H., Ban, L., Bythell, M., Card, T., …West, J. (2022). Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors. Blood, 140(Supplement 1), 2599-2600. https://doi.org/10.1182/blood-2022-158999

Background: Haemophagocytic Lymphohistiocytosis (HLH) is a rare, life-threatening hyper-inflammatory syndrome triggered by constitutive and acquired risk factors including haematological malignancy, infection, auto-immunity and rheumatological diseas... Read More about Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors.

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe (2022)
Journal Article
Bishton, M. J., Salles, G., Golfier, C., Knauf, W., Bocchia, M., Turner, D., …Laribi, K. (2023). Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe. eJHaem, 4(1), 45-54. https://doi.org/10.1002/jha2.593

The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBC... Read More about Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe.

Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 (2022)
Journal Article
Liu, H., Stiller, C. A., Crooks, C. J., Rous, B., Bythell, M., Broggio, J., …West, J. (2022). Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. British Journal of Haematology, 199(5), 728-738. https://doi.org/10.1111/bjh.18459

This analysis is the largest population-based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD-O-3) coded Langerhans cell histiocy... Read More about Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019.

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (2022)
Journal Article
Nastoupil, L., Morschhauser, F., Scholz, C. W., Bishton, M., Yoon, S.-S., Giri, P., …Bartlett, N. L. (2022). P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 6(S3), 1015-1016. https://doi.org/10.1097/01.HS9.0000847368.92731.fb

Temporal trends in the incidence of haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003-2018 (2022)
Preprint / Working Paper
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T. R., …Crooks, C. J. Temporal trends in the incidence of haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003-2018

Background Haemophagocytic lymphohistiocytosis (HLH) is rare, results in high mortality and is increasingly being diagnosed. Little is known about what is driving the apparent rise in the incidence of this disease.

Methods Using national linked el... Read More about Temporal trends in the incidence of haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003-2018.

The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe (2022)
Journal Article
Bishton, M., Marshall, S., Harchowal, J., Salles, G., Golfier, C., Tucci, A., …Zinzani, P. L. (2022). The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe. Hematological Oncology, 40(3), 370-380. https://doi.org/10.1002/hon.2978

Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen... Read More about The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe.